NCT05434858View on ClinicalTrials.gov

Imagery as Biomarker of Gout

NAActive, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 9, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

September 9, 2029

Conditions
Hyperuricemia
Interventions
OTHER

Dual-energy CT (DECT) and ultrasound

DECT and ultrasound will be performed to clarify the pathological mechanisms responsible for the transition from asymptomatic crystalline deposition to gout, and the mechanisms involved in the transition from hyperuricemia to de novo crystalline deposition.

Trial Locations (1)

59462

Lille Catholic Hospital, Lille

All Listed Sponsors
collaborator

Auckland University

UNKNOWN

lead

Lille Catholic University

OTHER